Health ❯ Healthcare ❯ Clinical Trials

Drug Efficacy

Patient Outcomes Weight Loss Results Combination Therapy Side Effects Weight Loss Medications Semaglutide Weight Loss Drugs Weight Loss Studies Patient Safety Weight Loss Trials

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

Phase 3 trials showed roughly 56–59% reductions in LDL cholesterol and the pill will carry a $315 monthly list price.

Donanemab Slows Alzheimer's Decline, New AAIC Data Show

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

FDA Approves At‑Home Weekly Subcutaneous Starter Dose for Leqembi

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

NICE Recommends First Vitiligo Repigmentation Cream for NHS Use in England

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

G-BA Finds No Added Benefit for Alzheimer’s Drug Leqembi in Germany

GLP‑1 Use Under Scrutiny After Study on Tolerability and Delhi OTC Sales